aclidinium vs roflumilast
Side-by-side comparison of aclidinium and roflumilast Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Tudorza Pressair
Daliresp
Duaklir Pressair is a combination medicine used to help people with COPD breathe better. It contains two medicines that open up the airways in your lungs.
Roflumilast (Daliresp) helps to reduce flare-ups in people with severe COPD. It is for people who also have chronic bronchitis and a history of COPD flare-ups.
Duaklir Pressair is used to treat chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that makes it hard to breathe. This medicine helps to open the airways and make it easier to breathe for people with COPD.
Roflumilast is used to lower your chances of COPD flare-ups. It is for adults with severe COPD linked to chronic bronchitis. You should have a history of COPD flare-ups to use this medicine.
Duaklir Pressair contains two medicines that work in different ways. One medicine relaxes the muscles around your airways, opening them up. The other medicine prevents the muscles from tightening.
Roflumilast blocks an enzyme called phosphodiesterase 4 (PDE4). By blocking PDE4, it reduces lung inflammation. This can help prevent COPD flare-ups.
- • Upper respiratory infection
- • Headache
- • Back pain
- • Diarrhea
- • Weight loss
- • Nausea
- • Headache
- • Back pain
- Difficulty breathing 1,869
- Inhaler not working correctly 1,281
- Skipped a dose of medicine 1,017
- Asthma 814
- Chronic obstructive pulmonary disease (COPD) 764
- Difficulty breathing 1,011
- Death 729
- Chronic lung disease 631
- Diarrhea 567
- Nausea 465
LABAs, such as formoterol fumarate, one of the active ingredients in DUAKLIR PRESSAIR, increase the risk of asthma-related death. Duaklir Pressair is not for asthma. Do not use Duaklir Pressair if you are allergic to milk proteins or any of the ingredients in it. Tell your doctor if you have heart problems, glaucoma, trouble urinating, diabetes, or seizures.
Roflumilast is not for sudden breathing problems. It may cause mental health problems, including suicidal thoughts. Tell your doctor if you have mood changes or weight loss.
It is not known if Duaklir Pressair will harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if this medicine passes into breast milk. Talk to your doctor about the best way to feed your baby if you are taking Duaklir Pressair.
It is not known if roflumilast is safe during pregnancy. Do not breastfeed while taking roflumilast.
Also Compare — Nearby Drugs
Compare aclidinium with
Compare roflumilast with
How to Read This aclidinium vs roflumilast Comparison
aclidinium is classified in the Long-Acting Muscarinic Antagonist (LAMA) drug class, while roflumilast sits within the PDE4 Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aclidinium has 5,745 submissions while roflumilast has 3,403. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between aclidinium and roflumilast — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.